Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Oct 25, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04801953 | Nimodipine in Vestibular Schwanommas | unknown | Phase 2 | 30 | Medical University of ViennaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT05229874 | Effect of CNSI vs. ICG in Lymph Node Tracing During Gastrectomy(FUTURE-01) | unknown | Phase 2 | 96 | Hebei Medical UniversityOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT06088056 | A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases | unknown | Phase 2 | 17 | Fudan UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06089330 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 102 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Oct 18, 2023 | clinicaltrials |
| NCT03638297 | PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer(PCOX) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | unknown | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04267315 | Trigger Point Injections for Post-Mastectomy Pain Syndrome | unknown | Phase 2 | 72 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05363007 | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma(SINAI) | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06083701 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | unknown | Phase 1 / Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06081582 | Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC | unknown | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06078657 | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06080854 | AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 108 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06060704 | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | unknown | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT03420014 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)(FIBROSARC US) | unknown | Phase 2 | 114 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04362722 | Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients(DUNCAN) | unknown | Phase 2 | 40 | Philogen S.p.A.INDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT05307198 | Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC(RAIC) | unknown | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | unknown | Phase 2 | 98 | Ho Sup LeeOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT05555017 | Tracer-Guided Surgery for Recurrent Prostate Cancer(Trace-II) | unknown | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05272462 | Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | unknown | Phase 2 | 34 | Loyola UniversityOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06065813 | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04754035 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia(IMPROVE) | unknown | Phase 2 | 31 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04856215 | 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia(RITII) | unknown | Phase 2 | 25 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04726215 | Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | unknown | Phase 2 | 50 | CellSight Technologies, Inc.INDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT06059885 | Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC | unknown | Phase 2 | 60 | Beijing 302 HospitalOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04074993 | Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | unknown | Phase 2 | 35 | JI-YOUN HANOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04259944 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | unknown | Phase 2 | 140 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04883814 | 18F-fluoroestradiol (FES) PET/CT for Breast Cancer | unknown | Phase 2 | 124 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05128630 | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.(DEDALUS) | unknown | Phase 2 | 45 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05174832 | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05800834 | Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds(MorphineGEL) | unknown | Phase 2 | 106 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05228496 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055166 | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | unknown | Phase 2 | 120 | Chongqing University Cancer HospitalOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05296577 | Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer | unknown | Phase 2 | 134 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05328440 | Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05768035 | Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide | unknown | Phase 1 / Phase 2 | 40 | Smart Immune SASINDUSTRY | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2023source: clinicaltrials